A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review
Metabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, such a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/7/1608 |
| _version_ | 1797588580463280128 |
|---|---|
| author | Ipek Cicekli Duygu Saglam Nadir Takar |
| author_facet | Ipek Cicekli Duygu Saglam Nadir Takar |
| author_sort | Ipek Cicekli |
| collection | DOAJ |
| description | Metabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, such as chronic inflammation, may have the same predictive potential as insulin resistance or MetS components in the genesis of type 2 diabetes and cardiovascular events. More importantly, the early diagnosis or treatment of MetS may significantly reduce the burden on the health systems of the disease with any prevention or biomarker and should not be underestimated. Osteopontin (OPN), also called secreted phosphoprotein 1, is a soluble protein found mostly in body fluids. Studies suggest that serum OPN levels may be an early and new biomarker to predict metabolic and cardiovascular complications significantly associated with some diseases. This review aims to provide specific insight into the new biomarker OPN in MetS. With this purpose, it is examined the link between the MetS cornerstones and OPN. In addition, the interaction between the microbiota and MetS is predicted to be bidirectional, and the microbiota may act as a bridge in this interaction process. Increased OPN levels may have unfavourable consequences for cardiovascular diseases, diabetes, and obesity, all of which are components of MetS. Further studies are required to evaluate the use of OPN levels as a clinical biomarker risk of MetS. |
| first_indexed | 2024-03-11T00:54:04Z |
| format | Article |
| id | doaj.art-9bd155a15245446396380d21196a69d4 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-11T00:54:04Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-9bd155a15245446396380d21196a69d42023-11-18T20:10:57ZengMDPI AGLife2075-17292023-07-01137160810.3390/life13071608A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive ReviewIpek Cicekli0Duygu Saglam1Nadir Takar2Department of Nutrition and Dietetics, Faculty of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, TurkeyDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Acibadem Mehmet Ali Aydinlar University, Istanbul 34752, TurkeyDepartment of Family Medicine, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul Provincial Directorate of Health, Istanbul 34865, TurkeyMetabolic syndrome (MetS) imposes a substantial burden on the healthcare systems and economies of countries and is a major public health concern worldwide. MetS is mainly caused by an imbalance between calorie intake and energy expenditure; however, it is recognized that additional variables, such as chronic inflammation, may have the same predictive potential as insulin resistance or MetS components in the genesis of type 2 diabetes and cardiovascular events. More importantly, the early diagnosis or treatment of MetS may significantly reduce the burden on the health systems of the disease with any prevention or biomarker and should not be underestimated. Osteopontin (OPN), also called secreted phosphoprotein 1, is a soluble protein found mostly in body fluids. Studies suggest that serum OPN levels may be an early and new biomarker to predict metabolic and cardiovascular complications significantly associated with some diseases. This review aims to provide specific insight into the new biomarker OPN in MetS. With this purpose, it is examined the link between the MetS cornerstones and OPN. In addition, the interaction between the microbiota and MetS is predicted to be bidirectional, and the microbiota may act as a bridge in this interaction process. Increased OPN levels may have unfavourable consequences for cardiovascular diseases, diabetes, and obesity, all of which are components of MetS. Further studies are required to evaluate the use of OPN levels as a clinical biomarker risk of MetS.https://www.mdpi.com/2075-1729/13/7/1608metabolic syndromeosteopontindiabetesobesityatherosclerosishypertension |
| spellingShingle | Ipek Cicekli Duygu Saglam Nadir Takar A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review Life metabolic syndrome osteopontin diabetes obesity atherosclerosis hypertension |
| title | A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review |
| title_full | A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review |
| title_fullStr | A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review |
| title_full_unstemmed | A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review |
| title_short | A New Perspective on Metabolic Syndrome with Osteopontin: A Comprehensive Review |
| title_sort | new perspective on metabolic syndrome with osteopontin a comprehensive review |
| topic | metabolic syndrome osteopontin diabetes obesity atherosclerosis hypertension |
| url | https://www.mdpi.com/2075-1729/13/7/1608 |
| work_keys_str_mv | AT ipekcicekli anewperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview AT duygusaglam anewperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview AT nadirtakar anewperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview AT ipekcicekli newperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview AT duygusaglam newperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview AT nadirtakar newperspectiveonmetabolicsyndromewithosteopontinacomprehensivereview |